The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...
There is more than one way to blockbuster product sales, and sometimes smaller might be better, writes Bennett Smith.
On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results